NLS PHARMACEUTICS LTD (NLSP)
Institutional ownership reported to the SEC as of Q3 2025, across 19 quarters.
3
Reporting holders
$263.1K
Reported value
0.0%
Held as options
-1
Holder change
Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| BVF INC/IL | $262.9K | 143,676 | 0.01% | 5q | HELD |
| UBS Group AG | $70 | 38 | 0.00% | 5q | -99.7%-$27.5K |
| CoreCap Advisors, LLC | $66 | 36 | 0.00% | 2q | HELD |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q3 2025 | 3 | $263.1K | 143,750 | 0 | 0 | 1 | 0.0% |
| Q2 2025 | 4 | $467.5K | 161,204 | 2 | 0 | 1 | 0.0% |
| Q1 2025 | 2 | $260.9K | 169,413 | 0 | 1 | 0 | 0.0% |
| Q4 2024 | 2 | $320.7K | 151,968 | 0 | 1 | 0 | 0.0% |
| Q3 2024 | 2 | $752.4K | 148,395 | 2 | 0 | 0 | 0.0% |
| Q2 2024 | 8 | $1.8M | 8,510,020 | 2 | 2 | 1 | 0.0% |
| Q1 2024 | 6 | $1.4M | 7,978,355 | 3 | 0 | 0 | 0.0% |
| Q4 2023 | 4 | $3.4M | 5,818,127 | 0 | 0 | 0 | 0.0% |
| Q3 2023 | 6 | $4.3M | 6,273,183 | 1 | 1 | 1 | 0.0% |
| Q2 2023 | 8 | $7.0M | 6,406,509 | 3 | 1 | 0 | 0.0% |
| Q1 2023 | 6 | $9.6M | 6,333,841 | 4 | 0 | 0 | 0.0% |
| Q4 2022 | 4 | $7.4M | 5,791,528 | 2 | 0 | 1 | 0.0% |
| Q3 2022 | 4 | $72.0K | 115,273 | 2 | 1 | 0 | 0.0% |
| Q2 2022 | 4 | $743.0K | 1,265,273 | 1 | 1 | 1 | 0.0% |
| Q1 2022 | 5 | $102.0K | 71,841 | 2 | 1 | 1 | 0.0% |
| Q4 2021 | 7 | $145.0K | 131,248 | 4 | 0 | 2 | 0.0% |
| Q3 2021 | 5 | $335.0K | 134,723 | 2 | 3 | 0 | 0.0% |
| Q2 2021 | 4 | $205.0K | 65,270 | 4 | 0 | 0 | 0.0% |
| Q1 2021 | 3 | $283.0K | 70,038 | 3 | 0 | 0 | 0.0% |